Virus

AV-Comparatives: Celebrating 20 Years of Excellence in Cybersecurity Testing

Retrieved on: 
Wednesday, March 20, 2024
EDR, Computer science, University, European, XDR, Virus, EPP, Risk management

INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.

Key Points: 
  • INNSBRUCK, Austria, March 20, 2024 /PRNewswire/ -- AV-Comparatives, an independent organisation that conducts comprehensive testing and evaluations of antivirus and security software, is celebrating its 20th anniversary.
  • Founded in 2004, AV-Comparatives has been active in the cybersecurity industry for over two decades, providing valuable insights into the effectiveness of various security solutions.
  • Read the full details here: https://www.av-comparatives.org/reports/anniversary-report-2004-2023-20-...
    The story of AV-Comparatives began in 1993 when Andreas Clementi was hit by a computer virus.
  • AV-Comparatives remains steadfast in its mission to foster a safer digital world through rigorous testing, insightful analysis, and unwavering dedication to excellence.

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

Retrieved on: 
Wednesday, March 20, 2024
Conference, Virus

HOUSTON, March 20, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024. Moleculin management will host a conference call and live webcast to discuss clinical, operational and financial results on Monday morning, March 25, 2024 at 8:30 AM ET.

Key Points: 
  • HOUSTON, March 20, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2023, on Friday afternoon, March 22, 2024.
  • Moleculin management will host a conference call and live webcast to discuss clinical, operational and financial results on Monday morning, March 25, 2024 at 8:30 AM ET.
  • Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call.
  • The live webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com , and will be archived for 90 days.

Moleculin Announces Reverse Stock Split

Retrieved on: 
Tuesday, March 19, 2024
CUSIP, Eastern Time Zone, Virus, Security (finance)

HOUSTON, March 19, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced a 1-for-15 reverse stock split of its common stock.

Key Points: 
  • HOUSTON, March 19, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced a 1-for-15 reverse stock split of its common stock.
  • The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
  • No fractional shares will be issued as a result of the reverse stock split.
  • As a result of the reverse stock split, the number of shares of common stock outstanding will be reduced from approximately 33.4 million shares to approximately 2.2 million shares, and the number of authorized shares of common stock will remain at 100 million shares.

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

Key protein linked to immune disorders

Retrieved on: 
Thursday, March 14, 2024
Health, B cell, Cell, Communication, Multiple sclerosis, Inflammation, Journal, Research, DSM-IV codes, Bacteria, Virus, Hokkaido University, Protein, Asthma, Cytokine, Infection, Immune system, Journal of Immunology, Antigen, Vaccine

SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

Key Points: 
  • SAPPORO, Japan, March 14, 2024 /PRNewswire/ -- A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells.
  • Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.
  • "Our findings provide valuable insights into the molecular mechanisms underlying T cell activation and the development of immune disorders," says Tadashi Matsuda, a Hokkaido University professor who led the study.
  • Future research can build on this work by exploring the potential of STAP-1 as a therapeutic target for treating immune-related disorders.

Global Markets and Technologies for Water Recycling and Reuse to Reach $31.9 Billion by 2028: BCC Research

Retrieved on: 
Thursday, March 14, 2024
Membrane, Dow, Growth, Environment, Biophysical environment, Recycling, Agriculture, Groundwater, Bacteria, Virus, Water resources, Human, River, Mineral, City, Plant, Drinking, Water, Oxygen, Pentair, Reclaimed water, Key market, Drinking water, Sewage treatment

BOSTON, March 14, 2024 /PRNewswire/ -- "According to the latest research study, the demand for Global Markets and Technologies for Water Recycling and Reuse expected to increase from $19.0 billion in 2023 to $31.9 billion by the end of 2028 at a compound annual growth rate (CAGR) of 11.0% during the forecast period 2023 to 2028."

Key Points: 
  • Global Water Recycling and Reuse Market by Sector:
    Municipal and Industrial: looks at how water recycling and reuse is used in different areas.
  • Global Water Recycling and Reuse Market by Technology:
    The Global Water Recycling and Reuse Market by Technology looks at different ways to clean and reuse water.
  • Global Water Recycling and Reuse Market by End Use:
    The "Global Water Recycling and Reuse Market by End Use" looks at how recycled water is used for different purposes.
  • Global Water Recycling and Reuse Market by Region:
    The "Global Water Recycling and Reuse Market by Region" looks at how water recycling and reuse are practiced in different parts of the world.

Safeguarding the Source: QNET Highlights the Importance of World Water Day and the Crucial Role of Home Water Filters

Retrieved on: 
Wednesday, March 13, 2024
UNSDG, World Health Organization, Health, Face, Shoulder, Public, QNET, Bacteria, Virus, Hope, Water resources, World Water Day, Reputation, Fresh water, Water, Drinking water, Bottled water

In the face of mounting global water crises, home water filters emerge as a beacon of hope, offering a tangible solution to ensure the purity of our most precious resource.

Key Points: 
  • In the face of mounting global water crises, home water filters emerge as a beacon of hope, offering a tangible solution to ensure the purity of our most precious resource.
  • The World Health Organization warns of the grave health risks posed by contaminated water sources, underscoring the urgency of securing a safe water supply .
  • Investing in home water filters isn't just about personal health; it's a collective commitment to safeguarding public health and well-being on a global scale.
  • Kuna also stated that "Investing in home water filters isn't merely a personal choice; it's a powerful statement in support of global water conservation efforts.

Crew-7 Astronauts Return to Earth After Nearly 200 Days Conducting Critical Science in Space

Retrieved on: 
Tuesday, March 12, 2024
SpaceX Crew-7, Emory University, Commercial Crew Program, European Space Agency, ZBLAN, JAXA, Biotechnology, Redwire, Growth, Medication, SPACE, Exploration, Patient, ISS National Lab, Research, University, Boeing, International Space Station, Bacteria, Virus, Software, Ageing, Glass, Liver regeneration, ProLiant, NASA, System, ISS, Therapy, SpaceX, HPE

Results from this project, funded by the U.S. National Science Foundation, could help boost our understanding of aging and its effects on disease mechanisms.

Key Points: 
  • Results from this project, funded by the U.S. National Science Foundation, could help boost our understanding of aging and its effects on disease mechanisms.
  • If successful, the powdered protein could help significantly reduce the mass of materials traveling to the space station, allowing more manufacturing at a lower cost.
  • The crew also continued work on a Boeing-sponsored investigation to test the effectiveness and durability of an innovative antimicrobial coating in space.
  • Findings will help advance heart disease modeling and could lead to the development of new therapies for patients on Earth.

Datasea to Drive Growth in its Acoustic Business via Product Upgrades and U.S. Market Entry

Retrieved on: 
Tuesday, March 12, 2024
Cloud, Development, RMB, White paper, Sterilization, RNA, Information technology, Acoustics, Welding, Virus, City, Research report, Infection, Intelligence, Ministry, Cloud computing, Ultrasound, Artificial intelligence, Medical imaging

This includes entering into agreements with new global manufacturing partners with specialized production facilities, and finalizing upgrades of several key acoustic disinfection products.

Key Points: 
  • This includes entering into agreements with new global manufacturing partners with specialized production facilities, and finalizing upgrades of several key acoustic disinfection products.
  • Ms. Zhixin Liu, CEO of Datasea, commented, "We believe that the introduction of upgraded acoustic disinfection products and their rapid market deployment will play a significant role in driving our financial performance in the periods ahead.
  • Datasea is a global initiator, promoter, and practitioner of acoustic concepts and is one of the pioneers in introducing the concept of acoustic effects globally.
  • In addition, the Company is actively expanding into fields with broad market prospects such as sound industry and sound agriculture.

Moleculin to Present at the 36th Annual ROTH Conference

Retrieved on: 
Tuesday, March 12, 2024
Conference, Virus, Broadcasting

HOUSTON, March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.

Key Points: 
  • Live webcast fireside chat on Monday, March 18th at 9:00 AM PT
    HOUSTON, March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.
  • In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the event, please visit the conference website .
  • A live webcast of the fireside chat will be available on the Events page in the Investors section of the Company's website ( moleculin.com ).